GCM
AGIO icon

Graham Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Graham Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-16,958
Closed -$480K – 989
2023
Q2 		$480K Buy
+16,958
New +$422K 0.01% 566
2022
Q4 		– Sell
-42,062
Closed -$1.19M – 1024
2022
Q3 		$1.19M Sell
42,062
-68,523
-62% -$1.84M 0.05% 407
2022
Q2 		$2.45M Buy
+110,585
New +$2.5M 0.1% 154

Other funds holding AGIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Graham Capital Management's AGIO Position: Q3 2023 in Review

Graham Capital Management sold out of Agios Pharmaceuticals (AGIO) in Q3 2023, closing a stake of 16,958 shares — an estimated $480K sold.

Graham Capital Management first reported a position in AGIO in Q2 2022 and held it in 3 quarters. The position peaked at $2.45M in Q2 2022. 144 funds tracked by Wall St. Rank hold AGIO as of Q3 2023.

  • Graham Capital Management reported no remaining Agios Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Graham Capital Management sold 16,958 Agios Pharmaceuticals shares in Q3 2023, an estimated $480K.
  • Graham Capital Management first reported a position in Agios Pharmaceuticals in Q2 2022 and held it in 3 quarters.
  • Graham Capital Management's Agios Pharmaceuticals position peaked at $2.45M in Q2 2022.
  • 144 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2023.

Based on Graham Capital Management's 13F filing for Q3 2023, filed 22 Nov 2023.